In a guest post in the Global Health Technologies Coalition’s “Breakthroughs” blog, “John Boslego, director of PATH’s Vaccine Development Global Program, writes about an innovative partnership between the United States and India to develop an oral vaccine against rotavirus diarrhea,” according to the blog. Since the vaccine “originated from an attenuated (weakened) strain of rotavirus that was isolated from an Indian child at the All India Institute of Medical Sciences in New Delhi in the mid-1980s … partners in the vaccine’s development have included DBT, Bharat Biotech, the [NIH], the [CDC], Stanford University School of Medicine, and PATH,” he notes, adding, “With the development costs shared by several partners, Bharat Biotech was able to commit to a price of $1.00 per dose for ROTAVAC®. As such, Bharat Biotech plans to register the vaccine for use in India first. If licensed by the Indian regulatory authority, the vaccine will be a more affordable alternative to the rotavirus vaccines already on the market” (6/19).